FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137405984> ?p ?o ?g. }

• W2137405984 endingPage "336" @default.
• W2137405984 startingPage "330" @default.
• W2137405984 abstract "Purpose A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2 + patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100. Patients and Methods Twenty-two patients (13 with glioblastoma multiforme [GBM], five with anaplastic astrocytoma [AA], three with anaplastic oligodendroglioma [AO], and one with anaplastic oligoastrocytoma [AOA]) received at least one vaccination, and 19 patients received at least four vaccinations at two αDC1 dose levels (1 × or 3 × 10 7 /dose) at 2-week intervals intranodally. Patients also received twice weekly intramuscular injections of 20 μg/kg poly-ICLC. Patients who demonstrated positive radiologic response or stable disease without major adverse events were allowed to receive booster vaccines. T-lymphocyte responses against GAA epitopes were assessed by enzyme-linked immunosorbent spot and HLA-tetramer assays. Results The regimen was well-tolerated. The first four vaccines induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant upregulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. Nine (four GBM, two AA, two AO, and one AOA) achieved progression-free status lasting at least 12 months. One patient with recurrent GBM demonstrated sustained complete response. IL-12 production levels by αDC1 positively correlated with time to progression. Conclusion These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines." @default.
• W2137405984 created "2016-06-24" @default.
• W2137405984 creator A5002668807 @default.
• W2137405984 creator A5002782232 @default.
• W2137405984 creator A5009472069 @default.
• W2137405984 creator A5014264452 @default.
• W2137405984 creator A5026029856 @default.
• W2137405984 creator A5032059835 @default.
• W2137405984 creator A5044474059 @default.
• W2137405984 creator A5050172772 @default.
• W2137405984 creator A5051030840 @default.
• W2137405984 creator A5057033838 @default.
• W2137405984 creator A5057531524 @default.
• W2137405984 creator A5057788524 @default.
• W2137405984 creator A5058793243 @default.
• W2137405984 creator A5062850215 @default.
• W2137405984 creator A5066986221 @default.
• W2137405984 creator A5073859061 @default.
• W2137405984 creator A5080784534 @default.
• W2137405984 creator A5085432609 @default.
• W2137405984 creator A5090079685 @default.
• W2137405984 creator A5091736003 @default.
• W2137405984 date "2011-01-20" @default.
• W2137405984 modified "2023-10-17" @default.
• W2137405984 title "Induction of CD8⁺ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma" @default.
• W2137405984 cites W1964968642 @default.
• W2137405984 cites W1966541541 @default.
• W2137405984 cites W1970597577 @default.
• W2137405984 cites W1976300861 @default.
• W2137405984 cites W1982752226 @default.
• W2137405984 cites W1991331687 @default.
• W2137405984 cites W1997424206 @default.
• W2137405984 cites W2006278799 @default.
• W2137405984 cites W2031325112 @default.
• W2137405984 cites W2034277378 @default.
• W2137405984 cites W2042268063 @default.
• W2137405984 cites W2054450974 @default.
• W2137405984 cites W2063640902 @default.
• W2137405984 cites W2065319085 @default.
• W2137405984 cites W2069220906 @default.
• W2137405984 cites W2071626601 @default.
• W2137405984 cites W2082226454 @default.
• W2137405984 cites W2089346214 @default.
• W2137405984 cites W2093783077 @default.
• W2137405984 cites W2094735628 @default.
• W2137405984 cites W2098267542 @default.
• W2137405984 cites W2105909083 @default.
• W2137405984 cites W2107277218 @default.
• W2137405984 cites W2109585496 @default.
• W2137405984 cites W2110632746 @default.
• W2137405984 cites W2110875829 @default.
• W2137405984 cites W2114071274 @default.
• W2137405984 cites W2115293121 @default.
• W2137405984 cites W2117735567 @default.
• W2137405984 cites W2122595817 @default.
• W2137405984 cites W2123909650 @default.
• W2137405984 cites W2124260598 @default.
• W2137405984 cites W2126432160 @default.
• W2137405984 cites W2127745545 @default.
• W2137405984 cites W2129387595 @default.
• W2137405984 cites W2137745459 @default.
• W2137405984 cites W2141099036 @default.
• W2137405984 cites W2143739956 @default.
• W2137405984 cites W2144182715 @default.
• W2137405984 cites W2144219560 @default.
• W2137405984 cites W2144616410 @default.
• W2137405984 cites W2145897029 @default.
• W2137405984 cites W2152767191 @default.
• W2137405984 cites W2152981221 @default.
• W2137405984 cites W2154478576 @default.
• W2137405984 cites W2155367074 @default.
• W2137405984 cites W2162630386 @default.
• W2137405984 cites W2163458899 @default.
• W2137405984 cites W2166637991 @default.
• W2137405984 cites W39922968 @default.
• W2137405984 cites W4252910285 @default.
• W2137405984 doi "https://doi.org/10.1200/jco.2010.30.7744" @default.
• W2137405984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3056467" @default.
• W2137405984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21149657" @default.
• W2137405984 hasPublicationYear "2011" @default.
• W2137405984 type Work @default.
• W2137405984 sameAs 2137405984 @default.
• W2137405984 citedByCount "496" @default.
• W2137405984 countsByYear W21374059842012 @default.
• W2137405984 countsByYear W21374059842013 @default.
• W2137405984 countsByYear W21374059842014 @default.
• W2137405984 countsByYear W21374059842015 @default.
• W2137405984 countsByYear W21374059842016 @default.
• W2137405984 countsByYear W21374059842017 @default.
• W2137405984 countsByYear W21374059842018 @default.
• W2137405984 countsByYear W21374059842019 @default.
• W2137405984 countsByYear W21374059842020 @default.
• W2137405984 countsByYear W21374059842021 @default.
• W2137405984 countsByYear W21374059842022 @default.
• W2137405984 countsByYear W21374059842023 @default.
• W2137405984 crossrefType "journal-article" @default.
• W2137405984 hasAuthorship W2137405984A5002668807 @default.
• W2137405984 hasAuthorship W2137405984A5002782232 @default.

• next